Transcriptogen

Transcriptogen Ltd is a biotechnology company focused on developing medical therapies for cancer using small molecules to inhibit the transcription of disease-related genes. The company was established in 2013 and has a lead molecule called TSG1301, which has shown effectiveness in treating breast and pancreatic cancer in human tumours grafted onto mice. Their approach aims to provide side-effect-free treatment with very low toxicity.

The lead molecule TSG1301 has been shown to be highly effective at treating breast and pancreatic cancer. These results were demonstrated in human tumours that were grafted onto mice, highlighting the company's focus on oncology and the development of medical therapies for these specific conditions.

Multiple reviewers praise Transcriptogen for providing top-notch genetic research services with exceptional quality and accuracy. They consistently note that the team is knowledgeable, professional, and efficient, delivering accurate results in a timely manner without any delays.

Transcriptogen holds a Trustburn rating of 4.1 out of 5 based on 11 reviews. The rating split includes several 5-star ratings, multiple 4-star ratings, and a few 3-star ratings, reflecting generally high satisfaction among users who have hired the company for genetic research and analysis.

Reviewers highlight that Transcriptogen provides reliable genetic testing services with results delivered accurately and on time. Customers also appreciate the friendly and helpful staff, as well as the responsive and helpful customer support team throughout the process.

News sources list Transcriptogen alongside other biotech companies such as Spirogen and Femtogenix. It is also noted in reports regarding late-stage drug discovery and translational research, co-founding Transcriptogen Ltd in 2013 alongside Femtogenix Ltd in 2015.

Dr Sheraz Gul is identified as a Visiting Professor and scientific co-founder of Transcriptogen Ltd. He has led work packages for numerous drug discovery projects and has coordinated work related to the company's development of medical therapies.

Transcriptogen uses a new approach involving small molecules to inhibit the transcription of disease-related genes. Transcription is the synthesis of RNA from a DNA template, a process that occurs in cell division, and this method is central to their strategy for treating cancer.

The official website domain for Transcriptogen is transcriptogen.com. This site serves as the primary online presence for the company, which was established to exploit growing interest in small molecule inhibitors for gene transcription.

Transcriptogen Ltd is registered in the United Kingdom with the company number 08461104. The company status is active, and it is based in the UK, focusing on oncology and the development of medical therapies.

Reviewers frequently mention the accuracy and quality of the work, the professionalism of the team, and the efficiency of the service delivery. They also highlight the responsiveness of the customer support team and the timely delivery of results.

Several reviews specifically praise the customer support team for being responsive and helpful. Users note that the support staff is friendly and assists them effectively throughout the process of obtaining genetic testing services.